Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Millet (Panicum miliaceum) is a non-standardized food allergenic extract used primarily for the diagnosis and treatment of IgE-mediated hypersensitivity. It belongs to the class of Non-Standardized Food Allergenic Extracts.
Name
Millet
Raw Name
MILLET
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
6
Variant Count
6
Last Verified
February 17, 2026
About Millet
Millet (Panicum miliaceum) is a non-standardized food allergenic extract used primarily for the diagnosis and treatment of IgE-mediated hypersensitivity. It belongs to the class of Non-Standardized Food Allergenic Extracts.
Detailed information about Millet
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Millet.
Millet belongs to a class of drugs called allergenic extracts. These are biological products used for two primary purposes: the diagnosis of specific allergies through skin testing and the treatment of allergic disease through allergen immunotherapy (hyposensitization). Historically, the FDA has permitted the use of these extracts based on their long-standing clinical history, though they are subject to rigorous manufacturing standards under the Center for Biologics Evaluation and Research (CBER).
The mechanism of action for Millet extract depends on its clinical application. In diagnostic skin testing, the extract is introduced into the skin (via prick or intradermal methods). If the patient has pre-existing IgE antibodies specific to millet proteins (such as prolamins or globulins), these antibodies, which are bound to the surface of mast cells, will cross-link upon contact with the millet allergens. This triggers the degranulation of mast cells, releasing histamine, leukotrienes, and other inflammatory mediators. This process results in a localized 'wheal and flare' reaction—a raised bump surrounded by redness—which is measured by the healthcare provider to confirm sensitization.
In allergen immunotherapy (AIT), the extract is administered in gradually increasing doses. The goal is to induce immunological tolerance. At the molecular level, this involves a shift in the immune response from a Th2-dominated profile (associated with allergy and IgE production) to a Th1-dominated profile. It also promotes the development of regulatory T cells (Tregs) and the production of 'blocking' antibodies, specifically IgG4. These IgG4 antibodies compete with IgE for allergen binding, effectively preventing the allergic cascade when the patient is naturally exposed to millet in their diet or environment.
Traditional pharmacokinetic parameters, such as bioavailability and half-life, are not typically established for allergenic extracts like Millet. Because these are complex biological mixtures rather than single chemical entities, their 'movement' through the body differs significantly from small-molecule drugs.
Millet extracts are primarily indicated for:
Millet allergenic extract is typically available in the following forms:
> Important: Only your healthcare provider can determine if Millet extract is right for your specific condition. The use of allergenic extracts must be conducted under the supervision of a physician trained in the management of anaphylaxis.
Dosage for Millet extract is highly individualized and must be determined by a specialist (allergist or immunologist). There is no 'standard' dose due to the non-standardized nature of the product.
Millet extract is used in children, but the procedure requires extreme caution. Dosing is generally similar to adults in terms of concentration, but the total volume administered during immunotherapy may be adjusted based on the child's size and sensitivity. Children are at a higher risk for systemic reactions, and testing should only be performed if there is a clear clinical history of millet sensitivity.
No specific dosage adjustments are provided for patients with renal impairment. However, since the clearance of inflammatory mediators released during a reaction depends on general physiological health, caution is advised.
No dosage adjustments are required for hepatic impairment. The proteins in the extract are not processed by the cytochrome P450 enzyme system.
Elderly patients may have reduced skin reactivity, leading to potential false-negative results in diagnostic testing. Additionally, the presence of comorbid cardiovascular disease in the elderly increases the risk of complications if a systemic reaction occurs.
Millet allergenic extract is never self-administered by the patient at home for diagnostic purposes. It is always administered in a clinical setting.
In the context of immunotherapy, a missed dose can disrupt the desensitization process. If a dose is missed by more than a week, the allergist will usually reduce the next dose to ensure safety before resuming the upward titration. If several weeks are missed, the build-up phase may need to be restarted from a much lower concentration.
An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level, leading to a systemic reaction.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing testing or treatment with Millet extract will experience localized reactions. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Millet and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
There is no evidence that long-term use of Millet allergenic extract causes chronic organ damage or increases the risk of cancer. However, the primary long-term risk is the 'priming' effect, where a patient becomes more sensitive to the allergen over time if the immunotherapy is not managed correctly. Some patients may develop 'serum sickness-like' symptoms (joint pain, fever, rash) if they receive high doses of foreign proteins over a very long period, though this is extremely rare with modern extracts.
While specific 'Millet' labels may vary by manufacturer, all allergenic extracts carry a general warning regarding Anaphylaxis.
Summary of Warning: This product can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. It must only be administered by healthcare providers prepared to manage such reactions. Patients with unstable asthma are at a higher risk for fatal outcomes. Patients must be observed for at least 30 minutes post-injection. Epinephrine must be immediately available.
Report any unusual symptoms to your healthcare provider.
Millet allergenic extract is a potent biological substance. It is only intended for use by physicians who are specifically trained in allergy and immunology. The most critical safety consideration is the risk of a systemic allergic reaction. Patients must be in a stable state of health before receiving the extract; for example, if a patient is currently experiencing an asthma flare-up or a severe respiratory infection, the administration should be postponed.
No FDA black box warnings specifically for 'Millet' exist as a standalone chemical, but the Allergenic Extract Class Warning applies to all such products. The warning emphasizes that these products can cause anaphylaxis and should only be used in facilities equipped with emergency resuscitation equipment, including oxygen, IV fluids, and intubation supplies.
Most patients can drive after the 30-minute observation period. However, if a patient experiences a systemic reaction or feels lightheaded/drowsy (sometimes a side effect of the antihistamines used to treat minor reactions), they should avoid driving until symptoms fully resolve.
Alcohol should be avoided for several hours before and after receiving Millet extract. Alcohol can increase blood flow to the skin and potentially accelerate the absorption of the allergen, increasing the risk of a systemic reaction. It can also mask the early symptoms of anaphylaxis.
Discontinuing Millet immunotherapy does not require a tapering process. However, the benefits of the treatment (tolerance) may gradually diminish over months or years once the injections are stopped. If the extract was being used for diagnostic purposes, there is no 'discontinuation' as it is a one-time or short-term procedure.
> Important: Discuss all your medical conditions with your healthcare provider before starting Millet.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Patients who are sensitive to Millet may show cross-reactivity with other members of the Gramineae (grass) family. This includes:
Patients should be monitored for 'pan-allergy' symptoms when exposed to these related species.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Millet.
Millet extract is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk to the fetus is not the extract itself, but the potential for maternal anaphylaxis, which can cause uterine contractions and fetal hypoxia (lack of oxygen). Starting the 'build-up' phase of immunotherapy is generally avoided during pregnancy. However, continuing a well-tolerated maintenance dose is often considered acceptable if the benefit to the mother outweighs the risk.
It is not known whether the components of Millet extract are excreted in human milk. However, because the extract consists of proteins that are likely digested in the infant's gut, the risk to a nursing child is considered minimal. The primary concern remains the mother's safety and the potential for a reaction that could interfere with breastfeeding.
Millet extract is used in children as young as 5 years old for diagnostic purposes. Immunotherapy in younger children (under 5) is rare and requires a very careful risk-benefit analysis, as young children may be unable to articulate the early symptoms of a systemic reaction. Growth and development do not appear to be affected by allergenic extracts.
In patients over 65, the skin's reactivity to allergens decreases (skin senescence). This can lead to smaller wheal sizes during testing, which may be misinterpreted as a lack of allergy. Furthermore, elderly patients are more likely to have underlying cardiovascular disease, making them more vulnerable to the complications of anaphylaxis.
There are no specific guidelines for the use of Millet extract in patients with renal failure or those on dialysis. Because the extract is biological and administered in minute quantities, it is generally considered safe, provided the patient is hemodynamically stable.
Hepatic impairment does not affect the processing of allergenic extracts. No dosage adjustments are necessary for patients with cirrhosis or other liver diseases.
> Important: Special populations require individualized medical assessment.
Millet extract contains specific allergenic proteins, primarily prolamins (storage proteins). When used diagnostically, these proteins bind to IgE antibodies on the surface of mast cells. This binding causes the IgE receptors (FcεRI) to cross-link, triggering a signal transduction cascade involving tyrosine kinases (like Syk). This leads to the release of pre-formed mediators (histamine, tryptase) and the synthesis of new mediators (prostaglandins, leukotrienes), resulting in the visible wheal and flare.
In immunotherapy, the repeated exposure to these proteins induces immune deviation. It increases the production of Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β) by regulatory T cells. These cytokines suppress the Th2 response and stimulate B cells to produce IgG4 instead of IgE. IgG4 acts as a 'blocking antibody,' preventing the allergen from reaching the mast-cell-bound IgE.
The pharmacodynamic effect of a diagnostic dose is rapid, with peak skin reactivity occurring at 15-20 minutes. The effect of immunotherapy is slow, often taking 6 to 12 months of regular injections before a significant reduction in clinical symptoms is observed. Tolerance can last for several years after a 3-to-5-year course of treatment.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Local/Subcutaneous) |
| Protein Binding | Primarily to IgE and IgG4 |
| Half-life | Proteins: Minutes to Hours; Immunological Effect: Years |
| Tmax | 15-20 minutes (for skin reaction) |
| Metabolism | Proteolysis by tissue enzymes |
| Excretion | Renal (as peptides/amino acids) |
Millet is a Non-Standardized Food Allergenic Extract. It is grouped with other cereal grain extracts like rye, barley, and oat extracts. Unlike 'Standardized' extracts (e.g., Cat Hair or Short Ragweed), its potency is not validated against a standard reference serum in a laboratory bioassay.
Common questions about Millet
Millet extract is primarily used as a diagnostic tool to identify individuals who have a specific IgE-mediated allergy to millet grain. By performing a skin prick test with the extract, healthcare providers can observe whether a localized allergic reaction occurs, confirming sensitivity. In some specialized clinical settings, it may also be used for allergen immunotherapy, which involves giving gradually increasing doses of the extract to help the body build up a tolerance to millet. This is particularly important for patients who experience severe reactions to this grain in their diet. It is not used to treat general nutritional deficiencies or non-allergic conditions.
The most common side effects are localized to the site where the extract was applied or injected. During a skin test, most patients will experience an itchy, red bump known as a wheal and flare, which typically fades within a few hours. For those receiving immunotherapy injections, swelling, redness, and itching at the injection site are very common and can last for a day or two. Some patients may also experience mild systemic symptoms like sneezing, a runny nose, or slight fatigue. While these are usually not dangerous, they should always be reported to the administering physician to ensure the dosage is appropriate.
It is strongly advised to avoid alcohol consumption on the days you receive a Millet extract injection or undergo skin testing. Alcohol can increase blood flow to the skin and dilate blood vessels, which may cause the allergen to be absorbed more quickly into your bloodstream, increasing the risk of a serious systemic reaction. Furthermore, alcohol can impair your ability to recognize the early warning signs of anaphylaxis, such as dizziness or mild nausea. To ensure maximum safety, most allergists recommend abstaining from alcohol for at least 24 hours around the time of your appointment. Always follow the specific safety protocols provided by your allergy clinic.
The use of Millet allergenic extract during pregnancy is approached with significant caution. While the extract itself is not known to cause birth defects, the risk of a systemic allergic reaction (anaphylaxis) poses a danger to both the mother and the fetus by potentially reducing oxygen supply. Most healthcare providers will not start a new course of immunotherapy while a patient is pregnant. However, if a woman is already on a stable maintenance dose and is tolerating it well, the doctor may decide to continue the treatment. Skin testing is also usually postponed until after delivery unless it is absolutely necessary for immediate medical management.
If the extract is being used for diagnostic skin testing, the results are almost immediate, typically appearing within 15 to 20 minutes of application. However, if it is being used for immunotherapy to build tolerance, the process is much slower. Most patients do not notice a significant reduction in their allergic sensitivity until they have reached their maintenance dose, which usually takes 3 to 6 months of weekly injections. Full clinical benefits and long-term immunological changes often require 12 months or more of consistent treatment. Most allergists recommend continuing the therapy for 3 to 5 years to ensure the tolerance lasts after the injections are stopped.
Yes, you can stop Millet immunotherapy injections suddenly without experiencing 'withdrawal' symptoms like those seen with certain medications. However, stopping the treatment prematurely will likely result in the return of your original allergy symptoms, as your immune system has not had enough time to develop long-term tolerance. If you miss doses for a period and then decide to restart, you cannot simply resume at the previous dose; your doctor will need to lower the dose and gradually build it back up to ensure your safety. Always discuss your plans with your allergist before stopping, as they can help you weigh the risks of symptom recurrence.
If you miss a scheduled immunotherapy injection of Millet extract, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to 'double up' on your next dose or take an extra dose at home. The safety of immunotherapy depends on a very specific schedule of gradual increases. If too much time passes between injections, your sensitivity to the allergen may increase, making your previous dose potentially dangerous. Your doctor will determine if your next dose needs to be reduced based on how much time has elapsed since your last injection. Consistent attendance is key to the success and safety of the treatment.
There is no clinical evidence to suggest that Millet allergenic extract causes weight gain. Unlike systemic corticosteroids or certain psychiatric medications, allergenic extracts are biological proteins administered in very small quantities and do not affect the body's metabolism or appetite regulation. Any weight changes observed during treatment are likely due to other factors, such as lifestyle changes, other medications, or underlying health conditions. If you are concerned about weight gain, you should discuss it with your healthcare provider to identify the actual cause. The extract's primary action is limited to the immune system's response to specific proteins.
Millet extract can interact with several types of medications, some of which can make the treatment dangerous. The most significant interaction is with beta-blockers, which are used for heart conditions and migraines; these can prevent life-saving epinephrine from working if you have a severe reaction. Antihistamines and certain antidepressants must be stopped before skin testing because they can hide the results. Other medications, like ACE inhibitors, may increase the severity of an allergic reaction. It is vital that you provide your allergist with a complete and updated list of all medications, including over-the-counter drugs and herbal supplements, before starting any treatment with Millet extract.
The concept of 'generic' vs. 'brand name' is different for allergenic extracts than for standard pills. Millet extract is a biological product, and while several different manufacturers (such as Greer Laboratories or HollisterStier) may produce it, they are not considered 'generics' of one another in the traditional sense. Each manufacturer's extract may have slight variations in protein composition and potency because they are non-standardized products. Therefore, once you start immunotherapy with a specific manufacturer's extract, your doctor will usually try to keep you on that same brand to ensure consistency in your treatment and to minimize the risk of unexpected reactions.